Generation Bio is a technology company.
Generation Bio has raised $135.0M across 2 funding rounds.
Key people at Generation Bio.
Generation Bio has raised $135.0M in total across 2 funding rounds.
Key people at Generation Bio.
Generation Bio has raised $135.0M in total across 2 funding rounds.
Generation Bio's investors include Atlas Venture, General Atlantic.
Generation Bio is a biotechnology company developing genetic medicines using proprietary platforms to treat inherited diseases and T cell-driven autoimmune conditions. It builds cell-targeted lipid nanoparticles (ctLNP) combined with siRNA to selectively deliver therapeutics to T cells in vivo, enabling potent gene silencing while sparing other immune cells and organs like the liver and spleen[1][2][3][4]. The company serves patients with genetic disorders and autoimmune diseases (e.g., those involving autoreactive T cells causing tissue damage), solving unmet needs by targeting undruggable T cell targets with tunable, redosable therapies that offer superior selectivity, potency, and safety over antibodies or small molecules[2][3][4]. Originally focused on its ceDNA platform for gene therapies, it has pivoted to ctLNP-siRNA for autoimmune applications, with plans to announce a lead target in mid-2025 and file its first IND in late 2026, signaling building momentum toward clinical validation[1][4].
Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Massachusetts[1]. While specific founder names are not detailed in available sources, the company emerged from efforts to advance next-generation genetic medicines, initially leveraging the ceDNA platform for durable, redosable gene therapies targeting inherited diseases[1][6]. A pivotal shift occurred toward T cell reprogramming using ctLNP technology, driven by recognition of T cells as master regulators in autoimmune pathology; early traction includes proprietary stealth tech for low clearance (<1% in liver/spleen) and modular design for broad payloads[2][3][4]. Backed by investors like Foresite Capital, it has evolved into a team of industry experts focused on autoimmune breakthroughs[4][6].
Generation Bio rides the T cell-targeted therapeutics wave in autoimmune diseases, where autoreactive T cells drive inflammation in high-unmet-need areas like tissue destruction disorders. Timing aligns with advances in LNP delivery (post-mRNA vaccine era) and siRNA maturation, enabling first-time access to undruggable T cell targets beyond surface-acting antibodies[2][3][4]. Market forces favoring it include demand for precise, tolerable immunomodulators amid failures of broad immunosuppressants, plus modular tech opening broad indications[4]. It influences the ecosystem by pioneering ctLNP for immune cell selectivity, potentially expanding siRNA beyond liver targets and reshaping autoimmune treatment paradigms[2][3].
Generation Bio is positioned for a transformative leap with its ctLNP-siRNA platform, announcing a lead autoimmune target mid-2025 and first IND in H2 2026, potentially validating T cell modulation's superiority. Trends like AI-driven target discovery and next-gen LNPs will accelerate its pipeline, while partnerships could amplify reach. Its evolution from ceDNA gene therapies to autoimmune precision positions it to redefine durable, selective treatments, enabling a new generation free from T cell-driven disease[1][2][4].
Generation Bio has raised $135.0M across 2 funding rounds. Most recently, it raised $110.0M Series C in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2020 | $110.0M Series C | Atlas Venture, General Atlantic | |
| Jan 1, 2018 | $25.0M Series A | Atlas Venture, General Atlantic |
